Stay updated with breaking news from Christopher yea. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 –CAMBRIDGE, Mass. & SALISBURY, England (BUSINESS WIRE) $KALV KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule pro. ....
KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) is set to release its earnings data on Wednesday, July 5th. KalVista Pharmaceuticals Price Performance Shares of NASDAQ:KALV opened at $9.04 on Tuesday. The firm has a market capitalization of $308.90 million, a PE ratio of -2.53 and a beta of 1.06. The business has a 50-day moving average […] ....
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $9.52 and traded as low as $8.75. KalVista Pharmaceuticals shares last traded at $9.16, with a volume of 179,794 shares trading hands. Analyst Ratings Changes Several equities […] ....
Tang Capital Management LLC increased its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) by 77.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,196,446 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,396,446 shares during the […] ....